FDA issues Acceptable for Filing letter for Sparsha’s Fentanyl Transdermal System
Lannett Company, Inc. recently announced that an Acceptable for Filing letter has been issued to its strategic partner Sparsha Pharma USA, Inc. from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fentanyl Transdermal System. Read More »